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Background: To expedite diagnosis of serious bowel disease, efforts are required
to signpost patients with high-risk symptoms to appropriate care. Community phar-
macies are a recognised source of health advice regarding bowel symptoms. This
study aimed to examine the effectiveness of a validated self-administered question-
naire, Jodi Lee Test (JLT), for detection, triage and referral of bowel symptoms
suggestive of carcinoma, in pharmacies.
Method: ‘Usual Practice’ was monitored for 12 weeks in 21 pharmacies in Western
Australia, documenting outcomes for 84 clients presenting with bowel symptoms.
Outcome measures were: acceptance of verbal advice from the pharmacist; general practitioner consultation; and diagnosis.
Trial of the JLT involved staff training in the research protocol and monitoring of outcomes for 80 recruited clients over 20
weeks. Utility of the JLT was assessed by post-trial survey of pharmacy staff.
Results: Significantly more referrals were made by staff using the JLT than during Usual Practice: 30 (38%) vs 17 (20%).
Clients’ acceptance of referrals was also higher for the intervention group (40% vs 6%). Two-thirds of pharmacy staff agreed
that the JLT could be incorporated into pharmacy practice, and 70% indicated they would use the JLT in the future.
Conclusion: A pre-post design was considered more appropriate than a randomised control trial due to an inability to match
pharmacies. Limitations of this study were: lack of control over adherence to the study protocol by pharmacy staff,\; no direct
measure of client feedback on the JLT; and loss to follow-up. The JLT was effective in prompting decision-making by phar-
macy staff and inter-professional care between pharmacies and general practice, in triage of clients at risk of bowel cancer.
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Background: To expedite diagnosis of serious bowel disease, efforts are required to signpost 
patients with high-risk symptoms to appropriate care. Community pharmacies are a 
recognised source of health advice regarding bowel symptoms. This study aimed to examine 
the effectiveness of a validated self-administered questionnaire, Jodi Lee Test (JLT), for 
detection, triage and referral of bowel symptoms suggestive of carcinoma, in pharmacies.  
Method: ‘Usual Practice’ was monitored for 12 weeks in 21 pharmacies in Western 
Australia, documenting outcomes for 84 clients presenting with bowel symptoms. Outcome 
measures were: acceptance of verbal advice from the pharmacist; general practitioner 
consultation; and diagnosis. Trial of the JLT involved staff training in the research protocol 
and monitoring of outcomes for 80 recruited clients over 20 weeks. Utility of the JLT was 
assessed by post-trial survey of pharmacy staff. 
Results: Significantly more referrals were made by staff using the JLT than during Usual 
Practice: 30 (38%) vs 17 (20%). Clients’ acceptance of referrals was also higher for the 
intervention group (40% vs 6%). Two-thirds of pharmacy staff agreed that the JLT could be 
incorporated into pharmacy practice, and 70% indicated they would use the JLT in the future.  
Conclusion: A pre-post design was considered more appropriate than a randomised control 
trial due to an inability to match pharmacies. Limitations of this study were: lack of control 
over adherence to the study protocol by pharmacy staff,\; no direct measure of client 
feedback on the JLT; and loss to follow-up. The JLT was effective in prompting decision-
making by pharmacy staff and inter-professional care between pharmacies and general 












Help seeking is considered to be the recognition of a health concern followed by a range of 
actions, one of which may be health service utilisation
1
. Interviews with people experiencing 
symptoms of bowel disease have shown that a significant proportion try to manage their own 
symptoms
2
, rather than consult a doctor, even when symptoms are persistent and 
subsequently found to be due to a life-limiting condition
3, 4
.  
A number of bowel (colorectal) diseases share clinical presentations, and certain symptom 
profiles that are associated with serious underlying conditions such as cancer, inflammatory 
bowel disease or degenerative bowel conditions
5
. To improve outcomes, people need to 
recognise the significance of their symptoms, and general practitioners need to accurately 
diagnose and manage bowel diseases
6, 7
. 
Faecal occult blood test screening (FOBT), available via the National Bowel Cancer 
Screening Program in Australia, is limited to people turning 50, 55, 60, 65 and 74 years (the 
average age of a patient with colorectal cancer is 68 years)
8
. Biennial screening for those 
aged 50-74 began in 2015 and is due to be completed in 2020
9
. Detection of blood in bowel 
motions (from the FOBT) prompts recommendations for further investigations such as 
colonoscopy
9
. At more than 30 times the price of FOBT, colonoscopy is too expensive for a 
population-based screening tool
9
.  Although FOBT is a valid test for bowel cancer, 
participation in the program is reportedly poor
10
, with barriers such as: “inconvenience of the 
testing process; aversion to manipulating faeces; cost; views about personal invulnerability; 
and cultural beliefs and attitudes”
11
. 
Community pharmacies are a recognised and common source of health advice for most 
Australians
12
. A survey of patients attending general practice in Australia indicated that other 









who might advise about bowel symptoms
13
. On average, three or more clients per week seek 
symptomatic treatment for bowel symptoms
13
 in each of Australia’s 5450 pharmacies
14
. 
Interactions between pharmacists and their symptomatic clients therefore offer an ideal 
opportunity to explore how pharmacy staff can complement larger-scale screening programs 
by identifying emerging serious illness. However, a survey of pharmacists in Australia
15
 
demonstrated a lack of awareness of high-risk bowel symptoms. This finding recognises 
 
the 
requirement for better education to understand when to refer for further medical 
investigation. 
Research supports the use of self-administered questionnaires to help primary health care 
professionals, in the course of routine conversations with clients, identify cases that warrant 
further investigation for colorectal pathology
16-18
. The Jodi Lee Test (JLT) is a simple, short, 
client-completed questionnaire developed to aid consultation between pharmacy staff and 
clients with bowel symptoms
19
.  The data provided can be reviewed by any pharmacy staff 
who interact with clients. For example, pharmacy assistants can use the data to determine 
when the client should be referred to the pharmacist, and pharmacists to determine when 
referral to a general practitioner is required
19
. The key items in the JLT indicating the need 
for referral for general practitioner assessment are the client’s symptom(s), symptom duration 
and history of gastrointestinal disease
19
. The JLT demonstrates high sensitivity (100%) and 
modest specificity (65%) for identification and triage of symptoms of bowel disease when 
compared to a validated tool, the Patient Consultation Questionnaire (PCQ)
19
. By 
comparison, the PCQ assists general practitioners in prioritising referrals for colorectal 
conditions, and has high sensitivity for serious colorectal pathologies
5,20
.  
The purpose of this study was to examine the feasibility and effectiveness of use of the JLT 
as a guide to pharmacy staff to identify clients with bowel symptoms warranting general 









MATERIALS AND METHODS 
Ethical approval was granted by the [name deleted for blind review] Human Research Ethics 
Committee (HR19_2013). This study used a prospective pre-post design in community 
pharmacies in Western Australia, and was conducted from May 2013 to March 2014. Prior to 
commencement of the intervention, data were collected concerning the usual practice (UP) of 
pharmacy staff dealing with clients seeking assistance for bowel symptoms. Following the 
UP phase, the JLT was introduced to guide the pharmacy staff in their interaction with the 
client (the intervention). These phases are described below. The value of the JLT was 
assessed between the two phases of the study by comparing the referrals to, and subsequent 
contact by the client with, the clients’ general practitioner for those considered to have signs 
of potentially serious disease. 
 
Sample size 
The personalised data collection and client follow-up warranted a manageable, localised 
sample for this feasibility trial, compared to large-scale screening programs. The previous 
development and validation study reported that 55% of clients who were screened using the 
JLT were indicated as requiring general practitioner referral
19
. For the purposes of this study, 
it was conservatively assumed the referral rate would reduce to approximately 35% after the 
pharmacist reviewed the completed questionnaire, communicated with the client, and applied 
his/her clinical judgement, in line with the protocol for use of the JLT. In the previous study, 
approximately 10% of eligible clients were referred to their general practitioner when the 
pharmacist was not using a decision support aid
13
. In order to detect a difference of this 
magnitude in the proportion of clients referred for further investigation ‘using’ versus ‘not 
using’ the decision-support aid (35% vs. 10%) with power=90% and α=0.05, 65 participants 
would be required in each arm of the trial. Allowing for an estimated 20% loss to follow-up, 









would recruit at least one participant each week, i.e. a one-in-three recruitment rate
15
, it was 
estimated that 20 pharmacies would be required to complete the study within the proposed 
timeframe. 
A convenience sample of 21 pharmacies in Western Australia was recruited to take part in the 
study: 17 in the Perth metropolitan area and four from regional towns. The locations of the 
pharmacies were selected to represent a range of socioeconomic areas. Data collection 
commenced with the UP phase; however, these data were not collected from two pharmacies 
that joined the study prior to the commencement of the intervention. Written consent was 
gained from all staff members of the pharmacies, including pharmacy assistants, pharmacists, 
pharmacists-in-training (pre-registered pharmacists) and locums, prior to commencement of 
the study.  Prior to commencement of each phase, author DS conducted a training session on 
the research protocol for the staff of each pharmacy. Instructions were given on recruitment 
of clients and study documentation. A written instruction sheet was left with each pharmacy 
for further reference, and staff were invited to report any queries or feedback. A feature of the 
JLT is that the pharmacist applies his/her interpretation of the questionnaire responses; as 
such, there was no training in clinical management of individual clients  
Baseline 
Staff members of the 21 intervention pharmacies completed a baseline survey comprising, a number 
of demographic questions and an open-ended question concerning their role in management of 
clients with bowel symptoms. Data were coded using key words elicited from the responses, and the 
roles of pharmacy assistants and pharmacists were determined collectively across the pharmacies. 
 
Usual-Practice Phase 
Pharmacy staff recruited consecutive clients seeking advice for bowel symptoms or seeking 
medicines normally used to treat diarrhoea, constipation or haemorrhoids. Participating 









in the study, which included contact by the researcher for follow-up after their pharmacy 
visit.  
The pharmacy staff continued their usual service in managing clients’ bowel symptoms. 
Consultations with consenting clients were documented by the pharmacists, recording the 
clients’ reported symptom(s), medication purchased, referrals for further investigation, and 
reasons for referrals. The pharmacies aimed to recruit and follow-up a total of 82 participants 
for this phase over a period of 12 weeks. 
Follow-up of the recruited clients took place four weeks following their pharmacy visit. The 
researcher contacted clients by telephone to determine if their symptom(s) persisted, whether 
referrals were acted upon, and if so, investigations undertaken by the general practitioner. 
Verbal consent for a second follow-up at a negotiated time, was obtained from those with 
pending investigations to determine their ultimate diagnosis. Participants who were not 
contactable for follow-up after three attempts were deemed lost to follow-up. 
 
Intervention (JLT) Phase 
Recruitment started four weeks after the completion of the UP Phase. The same eligibility 
criteria, client recruitment and follow-up processes were used for the Intervention Phase as 
for the UP Phase of the study. The Intervention pharmacies were those that completed the UP 
Phase 
In this phase, the pharmacy staff, following client consent, deployed the JLT to guide 
decision making in their consultation. The JLT, a paper-based questionnaire comprising eight 
questions, was self-completed by clients in a private or semi-private area in the pharmacy (if 
available), with the assistance of the staff member if required. On reviewing the completed 
JLT, the attending pharmacy assistant decided whether or not to refer the client to the 
pharmacist; likewise, the pharmacist applied his/her clinical judgement regarding referral to 









pharmacist completed details on a standard referral letter, issued to the client with the 
completed JLT and verbal recommendations. Verbal recommendations included sale of 
medicines, instructions for use of these medicines, and relevant warnings.  A carbon copy of 
the completed JLT was posted to the researcher in a reply-paid envelope following 
recruitment of each participant. The researcher contacted pharmacies twice per week by 
telephone and email to monitor and discuss their progress. The recruitment and follow-up 
period for this phase was extended to 20 weeks to account for increased pharmacy workload 
during December 2013 and January 2014.  
Similarly to the UP Phase, clients who were referred for consultation with a general 
practitioner were contacted by the researcher four weeks after their pharmacy visit to 
determine if they had visited their general practitioner, if any further investigation had taken 
place, and if a diagnosis had been made.  
 
Evaluation by Staff 
Within two weeks of the completion of the intervention phase, staff of the participating 
pharmacies were asked to complete a post-intervention feedback questionnaire to assess the 
utility of the JLT. The questions included the usability of JLT, reasons why the JLT had or 
had not been used during the consultation, intentions concerning use of the JLT in future, if 
they would recommend it to their colleagues, and which (if any) other symptoms would 
benefit from a questionnaire such as the JLT. 
 
Analysis 
The effectiveness of the JLT intervention was determined by: 
1. The proportion of clients who were referred to their general practitioner following use of 









2. Comparison of general practitioner attendance rates for clients referred to the general 
practitioner following use of the JLT compared to UP 
3. Diagnoses of colorectal pathologies in clients following the use of the JLT versus UP 
4. Feedback from pharmacy staff on the utility of the JLT. 
Demographic details of the study participants and baseline practice were summarised 
descriptively. Differences in referral rates and general practitioner consultations were 
assessed using the chi-square and Fisher’s exact test. The SPSS
®
 version 22 statistical 
software was used for all analyses. A p-value<0.05 was interpreted as indicating a 












One hundred and ninety-one pharmacy staff, comprising 122 pharmacy assistants, 62 
pharmacists and seven pre-registered pharmacists, completed the baseline survey. The mean 
age for pharmacy assistants was 28 years (range: 15-62 years), and 32 years (range: 22-56 
years) for pharmacists and pre-registered pharmacists. Pharmacists and pre-registered 
pharmacists had around 10 years’ work experience in pharmacy, while the pharmacy 
assistants recorded approximately six years. Twenty-one percent of the pharmacy assistants 
were tertiary educated, and 44% had completed year 12 or equivalent. Self-reported data 
from the participating pharmacies revealed pharmacy assistants typically gathered 
information about clients’ symptoms, history and lifestyle. The pharmacists offered advice on 
managing symptoms and lifestyle, and provided further information about the symptoms, 
medication and referral to a general practitioner.  
 
Assessment of the JLT Intervention 
Eighty-four clients were recruited from 19 pharmacies and followed up over 12 weeks in the 
UP Phase (Table 1); these comprised 60 (71%) females and 24 (29%) males. Twenty-one 
were lost to follow-up, and seven were excluded on the basis of age.  
Only 19 of the 21 selected pharmacies recruited clients for JLT phase. Eighty clients were 
recruited and followed up over 20 weeks in the Intervention Phase, comprising 54 (68%) 
females and 26 (33%) males. Fourteen were lost to follow-up. 
Fifty of the 80 clients (63%) were initially identified on self-completion of the JLT as 
meriting referral to a general practitioner. However, during the ensuing consultation, only 30 
(38%) were confirmed by pharmacists as warranting referral. Common reasons why the 
pharmacists did not refer cases indicated by the JLT as warranting further consideration were 









advice, or that the presenting symptom was an obvious side effect of a prescription 
medication the client was taking. 
The intervention was associated with a significantly higher referral rate during the 
Intervention Phase compared to the UP Phase: 38% vs 20% (Table 1). The acceptance of the 
recommendation to consult a general practitioner (i.e. attendance rate for general practitioner 
consultation) was also higher during the Intervention Phase: 40% vs 6%. Three clients from 
each of the UP and the Intervention Phases who were referred to consult a general 
practitioner were lost to follow-up. The p-value (Fisher’s Exact test) for comparison of the 
proportions of clients who were recommended to consult a general practitioner (1/14 and 
12/27, excluding those lost to follow-up), was 0.031. More diagnoses were made for clients 
who consulted a general practitioner following the pharmacist’s referral using the JLT, while 
there was no definitive diagnosis for the one client from the UP group who consulted a 
general practitioner. No diagnosis of bowel cancer was reported during the study, although 
several clients reported that their general practitioner had commenced monitoring. 
 
Pharmacy Evaluation 
Forty-seven pharmacy staff completed the feedback questionnaire. In this evaluation, each of 
the 19 participating pharmacies was represented by at least one full-time pharmacist and one 
pharmacy assistant. The respondents comprised 19 pharmacists and 27 pharmacy assistants. 
Twenty-one (45%) reported using the JLT when consulting clients with bowel symptoms. 
Thirty (64%) of the pharmacy staff agreed that the JLT could be incorporated in the 
pharmacy, and 33 (70%) indicated they would use the JLT in future when managing clients 
with bowel symptoms. 
The effectiveness of JLT is illustrated by the following quotations from pharmacy staff: 










“Confirming ‘red flags’ for early detection of bowel signs and symptoms that warranted 
referral for medical advice” (pharmacist). 
“Establishing consistent practice in the pharmacy” (pharmacist). 
“Providing timely, effective professional advice and information to clients, including advice 
about consulting a general practitioner” (pharmacist). 
“Helpful in reinforcing the case of referral when the client was initially hesitant to see the 
general practitioner” (pharmacist). 
 
Additional feedback related to the JLT being simple and quick to use, easy to understand by 
the client, non-invasive, easier for clients who feel embarrassed to discuss their bowel 
symptoms, and a good checklist approach for quick response in a busy pharmacy. In 
critiquing the tool, some stated the study protocol booklet format was time consuming and a 
deterrent to the recruitment process. Reasons given by staff for not using the JLT were 
largely logistical, including workflow, lack of private consultation space in their pharmacy, 
and few clients perceived as eligible. Other conditions for which the pharmacy staff would 
accept a JLT-like questionnaire were urinary tract infections, asthma, vaginal candidiasis, 










This prospective study supports the use of a brief self-administered questionnaire, the JLT, as 
a clinical decision tool for pharmacy staff to identify symptoms that might require medical 
investigation. It also serves as a written referral to the general practitioner. Capitalising on the 
personalised nature and convenience of pharmacist-client consultations, this intervention has 
the potential to complement larger-scale bowel cancer screening programs. Staff in the 
pharmacy were made aware of people who were presenting with symptoms that may require 
medical assessment. The client and the pharmacist were afforded the opportunity to discuss 
these in detail, and in some cases, referral was considered unnecessary. A reasonable 
assumption was made by the pharmacists that if a client had recently consulted a general 
practitioner, the general practitioner was almost certainly aware of the symptom(s) and was 
managing the client appropriately. Other clinical situations may have also overridden a 
pharmacist’s decision to refer a client. 
In cases where referral was warranted, the participants were advised of the need for a medical 
consultation and given a referral letter to take to the general practitioner. Use of the JLT 
resulted in 38% of clients being referred to their general practitioner, compared to 20% 
during UP. This result is in line with studies reporting that health questionnaires completed 
by patients frequently captured more positive symptoms than elicited during consultation
21, 22
. 
Our empirical evidence also indicates a greater proportion of the clients accepted referral. 
This finding is consistent with other studies that reported increased general practitioner 
consultation after being encouraged by a pharmacist
13, 23
.   
The concept of applying a decision-support tool in pharmacy practice was novel to our 
participating pharmacy staff, and although it may not be applicable to all practice settings or 
situations, the JLT shows promise in guiding management of bowel symptoms. In particular, 
the documentation of completed JLT and written referral, produced for cases warranting 









consult their general practitioner. Alternatively, for situations able to be managed in the 
pharmacy, the JLT highlights to the pharmacy staff member the presenting symptoms and 
their significance. 
As established in the baseline phase, the first point of contact for the client was commonly 
the pharmacy assistant. As such, prompting pharmacy assistants’ use of a simple, structured 
assessment tool can benefit the pharmacy workflow in triaging clients to be referred to the 
pharmacist and supporting the provision of non-prescription medicines; these are recognised 
roles for pharmacy assistants in Australia
24
. 
Most of the pharmacy staff found the JLT to be a simple and effective assessment guide for 
management of bowel symptoms, and reported that clients managed to complete the 
questions unassisted. As such, its deployment did not burden pharmacy staff. The majority of 
burden related to client recruitment and consent for research purposes (follow-up).  
Although a randomised control trial (RCT) is the ideal design to test pharmacy-led 
interventions; it was not feasible in this case for several reasons. Firstly, one of the objectives 
of the study was to identify if a change in referral practices of pharmacists could be achieved 
by introducing to them a structured questionnaire approach (the JLT) for these clients. Once 
the JLT is used for a particular client in a pharmacy, it would not be practical to revert to UP 
for a subsequent client. A cluster design where pharmacies applied only UP or the JLT would 
have avoided the issue of randomising clients, but differences between practices in terms of 
staffing and demographic profile may have confounded the analysis. For these reasons, a pre-
post design was considered the most appropriate.  
The study protocol was not consistently applied in some pharmacies, highlighting the 
challenges of research in a naturalistic setting. Although the researcher closely monitored the 
study progress, adherence to the study protocol by individual staff was not able to be 









supplement developmental research in its design
19
, and validation of client outcomes using 
general practice data. Further research on the acceptability of the JLT directly from the 
client’s perspective is required to determine their expectations of pharmacy services when 
presenting with bowel symptoms. Though a practising GP was involved in the design and 
validation stage of JLT
19
, no GPs to whom the clients were referred to, were asked to give 
feedback on the written referral that was given to clients whose symptoms warranted further 
medical consultation. Loss to follow-up is also recognised as a limitation in outcomes-
focussed research.  
Our findings suggest potential for wider application of the JLT as an optional practice-
enhancing guide to over-the-counter consultations in the community pharmacy setting. There 
is potential for the documentation to be adapted to guide management of other complex 
symptoms potentially warranting general practitioner investigation and potentially associated 
with early-stage cancer. There is potential for future research on development and trial of a 
JLT-like questionnaire for screening of pharmacy clients presenting with symptoms 











The JLT was found to be an acceptable assessment tool for the triage of bowel symptoms in a 
pharmacy setting. Its effectiveness was demonstrated by prompting a higher rate of referrals 
in those who would benefit from a general practitioner investigation, a higher rate of uptake 
of recommendations for referral and more clinical diagnoses compared to the usual model of 
consultation. As such, the JLT shows promise as an effective decision-making aid in the 
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Table 1. Impact Evaluation: Usual-Practice Phase versus Intervention Phase   
Variable Usual Practice Intervention 








1/17 (6%) 12/30 (40%)** 
Details of General 
practitioner 
Consultation 
#55: No follow-up 
for diagnosis 
#05: Monitored by general practitioner  
#07: Ultrasound  diverticulitis 
#13: Blood tests  monitored by general 
practitioner 
#26: No further action  
#41: No further action 
#51: Dairy allergy 
#55: Monitored by general practitioner 
#58: No follow-up for diagnosis 
#74: Blood and stool test  all clear 
#76: Stool test  all clear 
#80: Colonoscopy  monitored by general 
practitioner 
#83: Colonoscopy  monitored by general 
practitioner 
 
*   p=0.029 (chi-square) 
** p=0.017 (Fisher’s Exact) 
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